Haloperidol for the Treatment of Nausea and Vomiting in the ED
Haloperidol for the Treatment of Nausea and Vomiting in the ED
Single center, double-blind, randomized, controlled trial in patients who present to the
 emergency department (ED) with a chief complaint of nausea or vomiting. A total of 300
 patients age 18-55 presenting to the emergency department with chief complaint of nausea or
 vomiting will be enrolled from February 2021 - February 2022. Patients will be randomized and
 symptom levels will be recorded at 30, 60, 90, minutes. Follow-up will be performed by
 telephone at 24 hours.
Inclusion Criteria:

 -  presenting to the emergency department with chief complaint of nausea or vomiting

 Exclusion Criteria:

 -  abnormal blood pressure (>200/100mmHg or <90/40mmHg),

 -  fever (>100.4F),

 -  acute trauma,

 -  QT > 450ms on cardiac monitor,

 -  altered mental status (GCS < 15),

 -  chest pain,

 -  known allergy to haloperidol or ondansetron,

 -  Parkinson's disease,

 -  pregnancy or lactation,

 -  use of any antiemetic in the previous 8 hours,

 -  nausea and vomiting associated with vertigo,

 -  prisoners or any wards of the state.